10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
The biotechnology sector is expanding quickly due to rising demand for novel therapies, technological advances, and government assistance.
Kura Oncology Inc. (KURA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Suvretta Capital Management Aaron Cowen | 7,652,782 | $149,535,360 | +9% | 4.78% |
| 2. | EcoR1 Capital Oleg Nodelman | 5,806,871 | $113,466,259 | 3.88% | |
| 3. | Deerfield Management James E. Flynn | 5,411,571 | $105,742,097 | 1.57% | |
| 4. | VenBio Select Advisor Kurt Von Emster | 3,541,505 | $69,201,008 | 1% | |
| 5. | Biotechnology Value Fund / BVF Inc Mark Lampert | 3,371,761 | $65,884,210 | -18% | 1.92% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.50 | 50,000 | Director | 139,557 | 2023-06-16 | Filing | |
| $13.16 | 83,540 | Large Shareholder | 4,408,097 | 2018-12-21 | Filing | |
| $13.84 | 51,879 | Large Shareholder | 4,324,557 | 2018-12-19 | Filing | |
| $13.82 | 78,469 | Large Shareholder | 4,272,678 | 2018-12-18 | Filing | |
| $13.89 | 25,217 | Large Shareholder | 4,220,729 | 2018-12-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.03 | 526 | 23,184 | 2024-11-18 | Filing | ||
| $22.15 | 2,615 | 68,979 | 2024-05-20 | Filing | ||
| $17.80 | 963 | 48,093 | 2024-01-29 | Filing | ||
| $17.80 | 761 | 49,056 | 2024-01-29 | Filing | ||
| $17.80 | 594 | 49,817 | 2024-01-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,315,647 | $105,199,003 | 0% | |
| 2. | 4,037,691 | $58,061,996 | 0% | |
| 3. | 2,921,810 | $42,015,628 | 0% | |
| 4. | 2,001,754 | $28,784,934 | 0% | |
| 5. | 1,849,947 | $26,602,238 | 13.44% |
News See All
10 Most Promising Cancer Stocks According to Hedge Funds
According to the World Health Organization (WHO), cancer remains one of the leading causes of death globally, responsible for nearly 10 million deaths in 2020, or about one in six deaths worldwide.
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. Welcome to the Kura Oncology Third Quarter 2024 Financial Results Call. At this time, all participants are in a listen-only mode.
10 Best Small-Cap Healthcare Stocks To Buy Now
In difficult economic times, healthcare equities are sometimes regarded as a defensive investment.
Kura Oncology, Inc. (NASDAQ:KURA) Q2 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Q2 2024 Kura Oncology Conference Call. [Operator Instructions] Please note this event is being recorded.
Kura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Q1 2024 Kura Oncology Financial Results Conference Call. At this time, all participants are in listen-only mode.
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript
Kura Oncology, Inc. beats earnings expectations. Reported EPS is $-0.55, expectations were $-0.56. Kura Oncology, Inc.
5 Most Promising Cancer Stocks According to Analysts
In this piece, we will take a look at the five most promising cancer stocks according to analysts.
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Third Quarter 2023 Kura Oncology Inc. Earnings Conference Call. At this time, all lines are in listen-only mode.
14 Best Cancer Stocks To Buy Now
The global oncology landscape continues to evolve, with ongoing efforts to discover, develop, and provide innovative treatments aimed at improving outcomes for a growing number of patients.
Billionaire Hedge Funds
